DBV's Viaskin peanut patch safety study in toddlers nears its readout
COMFORT Toddlers will report adverse-event and serious-adverse-event data in a randomized, placebo-controlled safety design, feeding directly into DBV's planned BLA for 1-to-3-year-olds.
Executive Summary
- DBV Technologies is closing in on a safety readout that determines whether its peanut allergy patch can extend from older children into toddlers, the group where allergic reactions carry the highest risk.
- The study exists to support a regulatory filing already in motion, so the readout's main job is confirming the safety profile holds in a younger population, not proving a new efficacy signal.
- The trial has enrolled to its target without disruption and its completion timeline has not moved, which keeps the sponsor's own guidance window credible rather than raising execution concerns.
- No other program tests this exact epicutaneous mechanism in toddlers, so the readout mainly benchmarks against DBV's own earlier pediatric results rather than a rival's data.
The trial
COMFORT Toddlers (NCT07003919) is a randomized, placebo-controlled Phase 3 study assigning peanut-allergic children aged 1 through 3 to the Viaskin Peanut Patch or placebo, with two experimental arms and one placebo comparator arm. The primary endpoint is safety: adverse events, treatment-emergent adverse events, and serious adverse events collected during a double-blind, placebo-controlled treatment period. The trial has enrolled toward its 480-patient target across sites in the United States, Canada, the United Kingdom, Australia, France, Spain, Ireland, and the Netherlands, and its primary completion date is set for November 1, 2026. NCT07003919Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)NCT07003919
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What it will test
Because the primary endpoint is safety rather than an efficacy measure, the readout's information value lies in whether the adverse-event and serious-adverse-event rates in toddlers track the tolerability profile DBV has already reported in older children. DBV said in its 2025 annual results that it reported positive topline results from the Phase 3 VITESSE trial in peanut-allergic children aged 4 to 7, and that it initiated COMFORT Toddlers as a supplemental safety study for the younger cohort. The company also disclosed plans to submit a Biologics License Application for the 1-to-3-year-old population in the second half of 2026, which places COMFORT Toddlers' safety data on the direct path to that filing. DBVDBV Technologies Reports Full Year 2025 Financial Results and Business UpdateMar 26, 2026
Operational read
The trial has not moved its enrollment target and has not changed its primary completion date since starting, registering as a routine change level (Stable) with no amendment-driven instability. The trial moved from Not yet recruiting to Recruiting on June 27, 2025, shortly after its first registry posting on June 4, 2025, and has stayed on that status since. That combination, a filled enrollment target and an unmoved completion date, means the readout timeline is not the open question here; the endpoint result itself is. NCT07003919Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)NCT07003919
Competitive frame
DBV's own earlier Viaskin Peanut Phase 3 program in an older pediatric cohort is the closest precedent for this mechanism and modality. Other Phase 3 programs in peanut allergy, including AR101 oral immunotherapy from Aimmune Therapeutics, test a different modality (oral protein exposure rather than epicutaneous patch delivery), and antibody-based approaches such as ligelizumab and dupilumab target IgE or IL-4Rα signaling rather than epicutaneous tolerance induction. No competing program applies the same epicutaneous immunotherapy mechanism to peanut-allergic toddlers specifically, so the nearest benchmark for COMFORT Toddlers is DBV's own prior human data rather than a rival's readout.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.